Together, these data reveal that the MECOM down network is highly enriched in a subset of adult and pediatric AMLs with poor prognosis and can be integrated with currently available prognostic tools to improve risk stratification for patients with AML. This evidence concerns the gene MECOM and acute myeloid leukemia.